Showing results (21-30 of 114) with videos related to
Sort By:
Pageof 12
Seminars in Nuclear Medicine|October 16, 2020
Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future DirectionsMorten Busk, Jens Overgaard, Michael R HorsmanActa Oncologica (Stockholm, Sweden)|July 29, 2008
Resolution in PET hypoxia imaging: voxel size mattersMorten Busk, Michael R Horsman, Jens OvergaardRadiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 1, 2008
Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazoleRumi Murata, Michihiko Tsujitani, Michael R HorsmanPharmaceutics|December 5, 2013
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular TreatmentsThomas Nielsen, Thomas Wittenborn, Michael R HorsmanActa Oncologica (Stockholm, Sweden)|August 31, 2013
Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapyAne B Iversen, Morten Busk, Michael R HorsmanActa Oncologica (Stockholm, Sweden)|September 20, 2006
Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing responseMichael R Horsman, Thomas Nielsen, Leif Østergaard, et al.International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|April 19, 2016
Improving efficacy of hyperthermia in oncology by exploiting biological mechanismsNathalie van den Tempel, Michael R Horsman, Roland KanaarEJNMMI Radiopharmacy and Chemistry|June 17, 2020
In vitro hypoxia responsiveness of [18F] FDG and [18F] FAZA retention: influence of shaking versus stagnant conditions, glass versus polystyrene substrata and cell number down-scalingMorten Busk, Michael R Horsman, Jens Overgaard, et al.Cancer|June 16, 2004
Vascular-targeting therapies for treatment of malignant diseaseDietmar W Siemann, David J Chaplin, Michael R HorsmanCurrent Opinion in Investigational Drugs (London, England : 2000)|June 21, 2006
Current development status of small-molecule vascular disrupting agentsDavid J Chaplin, Michael R Horsman, Dietmar W SiemannPageof 12